Published in Medical Letter on the CDC and FDA, August 2nd, 2009
"REMS, or Risk Evaluation and Mitigation Strategy, requires a whole new mindset for many professionals in the industry," according to ParagonRx CEO Jeffrey Fetterman, "in that patient safety is no longer merely a statistic that is passively measured for regulatory compliance. Now, patient...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.